Founded in 1952, Bio-Rad Laboratories, Inc., is a Delaware corporation. The company is a multinational life sciences and clinical diagnostic company that develops, manufactures and sells a broad portfolio of instruments, systems, reagents and consumables. 

According to the 15-minute chart of Bio-Rad Laboratories A, a bearish trend has been established. The KDJ Death Cross and Bearish Marubozu at 09/10/2026 12:15 indicate that the momentum of the stock price is shifting towards the downside, with a high likelihood of further decreases. Sellers have taken control of the market, and the bearish momentum is expected to persist.A bearish trend has emerged in the 15-minute chart of Bio-Rad Laboratories A, as indicated by the formation of a KDJ Death Cross and a <a href="https://www.google.com/goto?url=CAESawHrOzAVVIWBfPxKZXZGNykVBMccvlx51K1cG7nRC7PqSLvZ4p6kcPlv442mDdFsO-LEBoBrcGh4FbYTPWIHmbHUyGfABdpGS76j5gge0YBU3R8bdkKrP7Cam3tDwBUGOBe-9sNX3HXCuSWE">Bearish Marubozu at 09/10/2026 12:15</a>. These technical signals suggest that the momentum of the stock price is shifting downward, with sellers currently dominating the market. The Death Cross, a technical pattern where the short-term moving average crosses below the long-term moving average, is often interpreted as <a href="https://www.google.com/goto?url=CAESawHrOzAVVIWBfPxKZXZGNykVBMccvlx51K1cG7nRC7PqSLvZ4p6kcPlv442mDdFsO-LEBoBrcGh4FbYTPWIHmbHUyGfABdpGS76j5gge0YBU3R8bdkKrP7Cam3tDwBUGOBe-9sNX3HXCuSWE">a sign of continued downward pressure</a>. In this case, the pattern reinforces the expectation of further price declines in the near term. The Bearish Marubozu, characterized by a long bearish candle with no upper shadow, further supports the view that bearish sentiment is intensifying. While historical data shows that the Death Cross does not always lead to prolonged bear markets, it has <a href="https://www.google.com/goto?url=CAESawHrOzAVVIWBfPxKZXZGNykVBMccvlx51K1cG7nRC7PqSLvZ4p6kcPlv442mDdFsO-LEBoBrcGh4FbYTPWIHmbHUyGfABdpGS76j5gge0YBU3R8bdkKrP7Cam3tDwBUGOBe-9sNX3HXCuSWE">frequently coincided with short-term market weakness</a>. Investors should remain cautious as the bearish momentum appears to be gaining strength.

BioRad实验室A

Bio-Rad Laboratories A Triggers KDJ Death Cross, Bearish Marubozu in 15min Chart

Bio-Rad Laboratories A's 15-minute chart has recently triggered a KDJ Death Cross and a Bearish Marubozu at 09/09/2026 16:00. This suggests a shift in the momentum of the stock price towards the downside, with a potential for further decreases in value. The bearish momentum is expected to continue as sellers maintain control of the market.On September 9, 2026, at 16:00, Bio-Rad Laboratories A (BIO) exhibited bearish signals on its 15-minute chart, including a KDJ Death Cross and a Bearish Marubozu candlestick pattern. These technical indicators suggest a shift in momentum toward the downside, with <a href="https://www.google.com/goto?url=CAESdQHrOzAVX-DyTYAf-zjTpyZ3LqfuEszF7R_38_sy8hyP6MZqC6AJhezn2Y48nKAtKoS8sRTwEQFoyhrK8c93kx1DmIDC-yY3k4vYglyXL_9ZAnzLhLbpAXh6_uJ98ylq1dMInZzQJ2IPVkZT6rGt_qYF0dlkFQ">sellers currently dominating the market</a>. The Bearish Marubozu, characterized by a long lower shadow and no upper shadow, indicates strong selling pressure and a potential continuation of the downward trend.Bio-Rad Laboratories, a key player in the medical devices industry, has a market capitalization of $10.32 billion and <a href="https://www.google.com/goto?url=CAES1AEB6zswFWyHrh24HMo_o40Bvuk5VYlLzuPzd1vGNoikjvDhlfqooVxCfmr5W9HkeaQ2WA8aGtt4DpXLju1MWT89VGScTKLLxfRrnojoVWwVP2-4MVLVi-JUxtoCENBMtNQg5Zc7logpncoEgHuXtVSeBn7qWsXjWK4G4dsWiWto2y7U6LXrhCFUIcNKvE0vSkfuBWkyjqZpQotF9s3I0dhsq-6lnVuJCLO64rYnkSpCkQrHCyVIHsvdl_1qBM7RTMARPTUmODpz62ixQyq056n8-nZdng">operates globally in life sciences</a>. The stock is currently trading at $386.11, near the upper end of its 52-week range of $241.71 to $390.34. Analysts have issued a mixed outlook, with one buy, three hold, and one sell rating, reflecting caution about the stock’s near-term prospects. The average analyst target price of $329.00 implies a potential downside of approximately -14.79%.Valuation metrics show a forward P/E ratio of 38.50, indicating expectations of future earnings growth, though the high ratio may suggest overvaluation relative to earnings. The company reported a slight revenue contraction of -0.10% and an EPS of 8.22, with a return on equity of 3.11%. Bio-Rad’s <a href="https://www.google.com/goto?url=CAES1AEB6zswFWyHrh24HMo_o40Bvuk5VYlLzuPzd1vGNoikjvDhlfqooVxCfmr5W9HkeaQ2WA8aGtt4DpXLju1MWT89VGScTKLLxfRrnojoVWwVP2-4MVLVi-JUxtoCENBMtNQg5Zc7logpncoEgHuXtVSeBn7qWsXjWK4G4dsWiWto2y7U6LXrhCFUIcNKvE0vSkfuBWkyjqZpQotF9s3I0dhsq-6lnVuJCLO64rYnkSpCkQrHCyVIHsvdl_1qBM7RTMARPTUmODpz62ixQyq056n8-nZdng">free cash flow of $283 million</a> supports operational sustainability and potential reinvestment in growth initiatives.The 50-day and 200-day moving averages stand at $336.20 and $302.00, respectively, reflecting an overall upward trend. However, the RSI of 32.83 suggests the stock is nearing oversold territory, while the <a href="https://www.google.com/goto?url=CAES1AEB6zswFWyHrh24HMo_o40Bvuk5VYlLzuPzd1vGNoikjvDhlfqooVxCfmr5W9HkeaQ2WA8aGtt4DpXLju1MWT89VGScTKLLxfRrnojoVWwVP2-4MVLVi-JUxtoCENBMtNQg5Zc7logpncoEgHuXtVSeBn7qWsXjWK4G4dsWiWto2y7U6LXrhCFUIcNKvE0vSkfuBWkyjqZpQotF9s3I0dhsq-6lnVuJCLO64rYnkSpCkQrHCyVIHsvdl_1qBM7RTMARPTUmODpz62ixQyq056n8-nZdng">MACD of 15.17 below</a> the signal line of 16.45 indicates bearish momentum.Investors should closely monitor these technical and fundamental indicators as Bio-Rad navigates a challenging market environment. While the bearish signals raise concerns, the company’s long-term strategic focus on innovation and market expansion remains a key factor in its investment profile.

Bio-Rad Laboratories A's 15-minute chart has recently exhibited a significant bullish trend. The occurrence of a KDJ Golden Cross and a Bullish Marubozu at 09/08/2026 14:00 indicates a shift in the momentum of the stock price towards the upside, suggesting a potential for further price appreciation. The dominance of buyers in the market and the continuation of bullish momentum are likely indicators of a sustained positive trend in the stock's performance.Recent technical analysis of Bio-Rad Laboratories A (BIO.AX) has revealed a notable bullish pattern on its 15-minute chart. At 14:00 on September 8, 2026, the stock formed a KDJ Golden Cross and a Bullish Marubozu candlestick, both of which are commonly interpreted as indicators of a potential upward shift in price momentum [1]. These signals suggest that buyers have taken control of the market at this point in time, with the continuation of bullish momentum indicating the possibility of further price appreciation [1]. Investors are advised to monitor the stock closely for confirmation of the trend through follow-through buying and sustained volume support. While technical indicators can provide insight into market sentiment and potential price direction, they should be considered alongside broader market conditions and fundamental analysis.

Bio-Rad Laboratories A triggers KDJ Golden Cross and Bullish Marubozu signal.

Bio-Rad Laboratories A's 15-minute chart has recently exhibited a downward trend, as evidenced by the Bollinger Bands Expanding Downward indicator, along with a Bearish Marubozu pattern observed on September 8, 2026 at 10:45. This suggests that market momentum is currently being driven by sellers, indicating a market controlled by bearish forces and likely to continue in this direction.Bio-Rad Laboratories A (ticker: BIOA) has recently displayed bearish signals on its 15-minute chart, raising concerns among short-term traders and technical analysts. On September 8, 2026, at 10:45, the stock formed a Bearish Marubozu candlestick pattern, characterized by a long bearish body with no upper shadow, indicating <a href="https://www.investopedia.com/terms/b/bollingerbands.asp">strong selling pressure</a> and a lack of buyer participation during the period. This pattern is often interpreted as a sign of a continuation of the downward trend, particularly when it appears in an established bearish context.In conjunction with the candlestick signal, the Bollinger Bands for the 15-minute timeframe have shown an expanding downward movement, suggesting <a href="https://www.trade-ideas.com/help/filter/Boll15/">increasing volatility and acceleration</a> of the decline. The widening of the bands reflects heightened market uncertainty and a shift in momentum toward sellers. When Bollinger Bands expand after a period of consolidation, it is often seen as a precursor to a breakout, though the direction of the breakout must be confirmed by subsequent price action.The combination of the Bearish Marubozu and the expanding Bollinger Bands indicates that the stock is currently under bearish control. Traders may interpret these signals as a continuation of the downward trend, with the lower Bollinger Band potentially acting as a support level or a target for further declines. However, as with all technical indicators, these signals should be used in conjunction with other forms of analysis, such as volume patterns or momentum oscillators, to <a href="https://www.investopedia.com/terms/b/bollingerbands.asp">confirm the bearish bias</a>.While these signals do not guarantee future price movements, they highlight the current market dynamics and the dominance of bearish sentiment. Investors and traders are advised to monitor subsequent price behavior and consider implementing risk management strategies, such as stop-loss orders, to mitigate potential downside exposure.

Bio-Rad Laboratories A's 15min chart triggers Bollinger Bands Expanding Downward, Bearish Marubozu.

Bio-Rad Laboratories A's 15-minute chart has triggered a significant technical indicator, a MACD Death Cross and KDJ Death Cross, which occurred on September 8, 2026 at 09:45. This event suggests that the stock price may continue to decline in the near future, as momentum shifts towards the downside. The stock price has the potential to further decrease as a result of this technical indicator.On September 8, 2026 at 09:45, Bio-Rad Laboratories (BIO) triggered two significant technical indicators on its 15-minute chart: the MACD Death Cross and the KDJ Death Cross. These signals are often interpreted as signs of a potential downward shift in momentum, suggesting <a href="https://finance.yahoo.com/quote/BIO/">further price declines in the near term</a>.As of September 3, 2026, the stock closed at $387.90, reflecting a <a href="https://www.macrotrends.net/stocks/charts/BIO/bio-rad-laboratories/stock-price-history">28.02% annual increase</a> compared to the year's opening price of $305.27. Over the past 52 weeks, the stock has ranged between a high of $396.23 and a low of $236.73, with an average price of $301.68. The current price is <a href="https://www.macrotrends.net/stocks/charts/BIO/bio-rad-laboratories/stock-price-history">39% above the 52-week low</a>.Bio-Rad Laboratories operates in the medical products manufacturing sector, with a market capitalization of $10.388 billion and <a href="https://www.macrotrends.net/stocks/charts/BIO/bio-rad-laboratories/stock-price-history">annual revenue of $2.583 billion</a>. The company's business is divided into two segments: Life Science and Clinical Diagnostics, both of which serve a broad range of healthcare and research markets.While technical indicators can provide insight into potential price movements, they should be considered alongside fundamental analysis and broader market conditions. Investors are advised to monitor the stock's performance closely in the coming days and weeks for further confirmation of the trend.

Bio-Rad Laboratories A Triggers MACD Death Cross and KDJ Death Cross

Catalyst<ul> <li>AiM Medical Robotics received a $2 million Phase II SBIR award from the NIH to advance its MRI-guided neurosurgery robotics systems.</li></ul>Risk<ul> <li>Fund flows are negative across all order sizes, with small, medium, large, and extra-large buckets showing outflow trends.</li></ul>

Key Factors

BIO shares rose 19.1% over the past month.Improved digital PCR demand and steady clinical diagnostics performance support BIO's recent momentum.BIO balances premium valuation against restructuring efforts aimed at enhancing profitability.

BIO News